Shaping the future of medicine with powerful therapeutic and diagnostic platforms
Novel cancer therapies combining Affimer® biotherapeutics and pre|CISION™ tumour microenvironment activation >
M&A led growth with a vision to build a European IVD business with global reach >
Growing shareholder value by developing novel cancer therapies and powerful diagnostics using our proprietary Affimer® and pre|CISION™ platforms. >
NOW IN CLINIC
AVA6000, tumour microenvironment activated chemotherapy, powered by the pre|CISIONTM platform.